Healthcare
Live Price
Offline$0.17
-5.56% today
1Y Change
-49.07%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sangamo Therapeutics, Inc. (SGMO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $0.17 and down 49.1% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -31.6%, EPS growth of +10.2%, a dividend yield of 0.0%. What stands out right now is revenue -31.6%, EPS +10.2%, free cash flow -44.4% with operating margin -273.1% and ROIC -566.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGMO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGMO Max Drawdown
-86.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGMO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$110.7M
-0.5% YoY
FY Net Income
-$178.3M
+7.3% YoY
Free Cash Flow
-$256.5M
-5.2% YoY
Revenue Growth
-31.6%
EPS Growth
+10.2%
Gross Margin
80.8%
Net Margin
-310.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40M | 58M | 176M | 111M | 111M |
| Gross Profit | 40M | 58M | 176M | 99M | 111M |
| Operating Income | -121M | -104M | -274M | -201M | -183M |
| EBITDA | -121M | -89M | -97M | -189M | -166M |
| Net Income | -123M | -98M | -258M | -192M | -178M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 42M | 45M | 100M | 179M |
| Total Assets | 60M | 102M | 165M | 563M | 722M |
| Total Liabilities | 74M | 79M | 82M | 268M | 347M |
| Shareholder Equity | -14M | 23M | 83M | 295M | 375M |
| Total Debt | 25M | 31M | 38M | 43M | 48M |
| Net Debt | 4M | -11M | -7M | -57M | -131M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
233M
-4.3% YoY
Capital Expenditures
23M
-15.4% YoY
Free Cash Flow
257M
-5.2% YoY
Key ratios
Gross Margin
80.8%
Operating Margin
-273.1%
Net Margin
-310.8%
ROE
-2983.2%
Debt / Equity
-1.88x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.